Invion (ASX:IVX) closes H1 with key R&D milestones for cancer and infectious diseases
- March 08, 2023 12:25 PM AEDT | Ankit Sethi
Highlights,Invion has released its H1FY23 report, highlighting progress with respect to its Photosoft™ technology and lead drug candidate INV043.,Photosoft™ has demonstrated positive results against antibiotic resistant MRSA bacteria, Candida albicans fun...
Aguia (ASX:AGR) advancing Brazilian phosphate and copper projects at brisk pace
- March 08, 2023 12:02 PM AEDT
- Team Kalkine Media
Aguia (ASX:AGR) raises AU$1.5Mn via private placement for Organic Phosphate Project
- March 08, 2023 12:00 PM AEDT
Aguia Resources (ASX:AGR) updates about positive outcomes of meeting related to PCA
- March 08, 2023 11:59 AM AEDT
- Ankit Sethi
Dundas project developments stand out in Catalina Resources (ASX:CTN) H1 report
- March 07, 2023 07:00 PM AEDT
- Team Kalkine Media
VRX Silica (ASX:VRX) signs LOI with ResourcesWA for power supply at Arrowsmith North
- March 07, 2023 03:35 PM AEDT | Manisha
Highlights,VRX Silica has executed a letter of intent (LOI) with ResourcesWA to explore a proposed power supply solution for the company’s Arrowsmith North Silica Sand Project.,Under the LOI, the company will analyse the potential to set up ...Read More...
Surefire’s (ASX:SRN) Victory Bore exploration target estimate confirms world-class vanadium project
- March 07, 2023 01:46 PM AEDT | Manisha
Highlights,The SRN stock jumped over 20 per cent on 07 March 2023.,Ticking off a major upgrade, Surefire Resources has announced the Exploration Target Estimate (ETE) for the Victory Bore vanadium project.,The ETE has been derived as a lowe ...Read More...
Wooboard (ASX:WOO) reports development milestones for Sixty wellness app in H1
- March 07, 2023 12:15 PM AEDT | Ankit Sethi
Highlights,Wooboard’s key highlight of the reported period is the new improvements to its Sixty wellness app.,The app added new features like Vimeo-powered live streaming, new chat system, and Spanish-language support.,WOO also retains its ...Read More...
Wooboard (ASX:WOO) announces issue of convertible notes worth AU$1Mn
- March 07, 2023 12:14 PM AEDT | Ankit Sethi
Highlights,Australia's WooBoard, a listed entity, has announced issuance of convertible notes worth AU$1 million,The terms include 6% p.a. coupon rate, which is payable after the end of the term (18 months),Clee Capital is the lead manager, ...Read More...
Radiopharm (ASX:RAD) ticks off key clinical milestones, supply agreements in H1
- March 07, 2023 11:44 AM AEDT | Team Kalkine Media
Highlights,Radiopharm Theranostics is developing a world‐class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.,For the first half ended 31 December, the company has reported encouragin ...Read More...
Carbonxt (ASX:CG1) H1 report highlights new carbon plant, contract renewal with largest customer
- March 06, 2023 07:53 PM AEDT | Team Kalkine Media
Highlights,Carbonxt performed maintenance and installation programs at its existing facilities during the first half, expected to boost its margin growth in 2023.,The company achieved crucial near-term objectives concerning its strategic KC ...Read More...
Chimeric Therapeutics (ASX:CHM) updates about fourth dose cohort in CHM 1101 study
- March 06, 2023 10:56 AM AEDT | Ankit Sethi
Highlights,Chimeric Therapeutics’ CHM 1101 (CLTX CAR T) therapy is undergoing trial at the City of Hope,This cell therapy is being designed to treat glioblastoma by Chimeric, Australia’s leader in cell therapy,The third dose cohort was comp ...Read More...
Radiopharm (ASX:RAD) acquires US-based therapeutic radiopharmaceuticals developer, boosts scientific advisory board
- March 03, 2023 02:52 PM AEDT | Team Kalkine Media
Highlights,Radiopharm Theranostics (ASX:RAD) is joining hands with Pharma15, a next-gen preclinical platform for therapeutic radiopharmaceuticals.,With this acquisition, the company will further improve its access to strong academic network ...Read More...
Imugene (ASX:IMU) doses first patients in combination study of VAXINIA MAST trial
- March 03, 2023 01:21 PM AEDT | Manisha
Highlights,Imugene has advanced its ongoing Phase 1 MAST study with the first patients receiving dosing in the intratumoral (IT) and intravenous (IV) cohorts of CF33-hNIS in combination with Pembrolizumab.,The study is focused on measuring ...Read More...
Cluey (ASX:CLU) successfully completes bookbuild for equity raising program
- March 03, 2023 12:40 PM AEDT | Ankit Sethi
Highlights,CLU has completed the bookbuild to raise approximately AU$8.2 million (Placement and Institutional Entitlement),Retail Entitlement Offer would open next week on 8th March to raise up to AU$2.4 million,CLU, the online tutoring lea ...Read More...